tiprankstipranks
Advertisement
Advertisement

MBRX Stock Latest News

Moleculin Biotech Stockholders Approve Warrant Share Issuance
Company AnnouncementsMoleculin Biotech Stockholders Approve Warrant Share Issuance
3d ago
8K
MBRX
Moleculin Biotech management to meet with Maxim
PremiumThe Fly
Moleculin Biotech management to meet with Maxim
16d ago
MBRX
Moleculin Biotech files to sell 6.37M shares of common stock for holders
PremiumThe Fly
Moleculin Biotech files to sell 6.37M shares of common stock for holders
21d ago
MBRX
Moleculin Biotech announces enrollment milestone in MIRACLE trial
PremiumThe Fly
Moleculin Biotech announces enrollment milestone in MIRACLE trial
26d ago
MBRX
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout
PremiumCompany Announcements
Moleculin Advances MIRACLE Trial, Prepares Interim AML Readout
26d ago
8K
MBRX
Moleculin Biotech: Attractive Risk/Reward Ahead of Pivotal Annamycin Phase 3 Readout Supports Buy Rating and $10 Target
PremiumRatingsMoleculin Biotech: Attractive Risk/Reward Ahead of Pivotal Annamycin Phase 3 Readout Supports Buy Rating and $10 Target
28d ago
MBRX
Moleculin Biotech Updates Investors with New Corporate Presentation
Premium
Company Announcements
Moleculin Biotech Updates Investors with New Corporate Presentation
30d ago
8K
MBRX
Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year
Premium
The Fly
Moleculin Biotech reports FY25 EPS ($28.42) vs. ($189.14) last year
30d ago
MBRX
Moleculin Biotech sees cash runway into 3Q26
PremiumThe Fly
Moleculin Biotech sees cash runway into 3Q26
30d ago
MBRX
MBRX Earnings this Week: How Will it Perform?
PremiumPre-Earnings
MBRX Earnings this Week: How Will it Perform?
1M ago
MBRX
Moleculin Biotech Raises Capital via Inducement Warrant Agreements
PremiumCompany Announcements
Moleculin Biotech Raises Capital via Inducement Warrant Agreements
2M ago
8K
MBRX
Early Efficacy Signal in Annamycin’s Phase 3 MIRACLE Trial Supports Buy Rating on Moleculin
PremiumRatings
Early Efficacy Signal in Annamycin’s Phase 3 MIRACLE Trial Supports Buy Rating on Moleculin
2M ago
MBRX
Moleculin Biotech announces exercise of warrants for $8.3M gross proceeds
PremiumThe FlyMoleculin Biotech announces exercise of warrants for $8.3M gross proceeds
2M ago
MBRX
Moleculin Biotech Issues New Investor Corporate Presentation
Premium
Company Announcements
Moleculin Biotech Issues New Investor Corporate Presentation
2M ago
8K
MBRX
Moleculin Reports Positive Progress in MIRACLE AML Trial
Premium
Company Announcements
Moleculin Reports Positive Progress in MIRACLE AML Trial
2M ago
8K
MBRX
Moleculin approach first unblinding of data from Phase 2B/3 study of Annamycin
PremiumThe Fly
Moleculin approach first unblinding of data from Phase 2B/3 study of Annamycin
2M ago
MBRX
Moleculin Biotech announces notice of allowance for JPO covering Annamycin
PremiumThe Fly
Moleculin Biotech announces notice of allowance for JPO covering Annamycin
2M ago
MBRX
Moleculin Gains Japanese Patent Allowance for Annamycin
PremiumCompany Announcements
Moleculin Gains Japanese Patent Allowance for Annamycin
2M ago
8K
MBRX
Moleculin Biotech announces launch of CEO Corner platform
PremiumThe Fly
Moleculin Biotech announces launch of CEO Corner platform
2M ago
MBRX
Moleculin Biotech Shareholders Approve Warrant Share Issuance
PremiumCompany AnnouncementsMoleculin Biotech Shareholders Approve Warrant Share Issuance
2M ago
8K
MBRX
Moleculin Biotech Updates Investors with New Corporate Presentation
Premium
Company Announcements
Moleculin Biotech Updates Investors with New Corporate Presentation
3M ago
8K
MBRX
De‑Risked Safety and Pivotal 2026 Catalyst Underpin Buy Rating on Moleculin’s Annamycin Oncology Franchise
Premium
Ratings
De‑Risked Safety and Pivotal 2026 Catalyst Underpin Buy Rating on Moleculin’s Annamycin Oncology Franchise
3M ago
MBRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >